Literature DB >> 8603604

Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat.

B A Crippes1, V W Engleman, S L Settle, J Delarco, R L Ornberg, M H Helfrich, M A Horton, G A Nickols.   

Abstract

The cell surface integrin, alphaVbeta3, is important for the attachment of osteoclasts to bone matrix and the subsequent resorption of bone. The present study was designed to determine the effects of F11, a monoclonal antibody to the rat beta3 subunit, on calcium mobilization in a rat model of bone resorption. Male Sprague Dawley rats became hypocalcemic within 18 h after thyroparathyroidectomy. Synthetic PTH-related protein (PTHrP(1-34)) administered to control rats caused serum calcium to return to normal. Anti-beta3 treatment of rats after thyroparathyroidectomy inhibited the calcemic response to PTHrP by 65%. Circulating F11 was biologically active as demonstrated by osteoclast retraction and by the inhibition of adenosine diphosphate-induced platelet aggregation via inhibition of the platelet integrin alphaIIbbeta3 in ex vivo assays. F11 antibody was localized by immunohistological staining to osteoclasts in long bones, suggesting that the mechanism of action of the antibody was via a direct effect upon osteoclasts. Echistatin and calcitonin also inhibited calcemic responses to PTHrP in this in vivo model, whereas an isotype-matched, control antibody was ineffective. These studies provide the first direct evidence in vivo that osteoclast-mediated bone resorption is regulated via beta3 integrin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603604     DOI: 10.1210/endo.137.3.8603604

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

Review 1.  Regulation of osteoclast formation and function.

Authors:  L T Duong; G A Rodan
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 2.  Involvement of alpha(v)beta3 integrins in osteoclast function.

Authors:  Ichiro Nakamura; Le T Duong; Sevgi B Rodan; Gideon A Rodan
Journal:  J Bone Miner Metab       Date:  2007-10-25       Impact factor: 2.626

3.  Integrin targeted therapeutics.

Authors:  Melissa Millard; Srinivas Odde; Nouri Neamati
Journal:  Theranostics       Date:  2011-02-17       Impact factor: 11.556

Review 4.  Targeting integrins to promote bone formation and repair.

Authors:  Pierre J Marie
Journal:  Nat Rev Endocrinol       Date:  2013-01-29       Impact factor: 43.330

5.  Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption.

Authors:  H Yoshitake; S R Rittling; D T Denhardt; M Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

6.  The type II collagen N-propeptide, PIIBNP, inhibits cell survival and bone resorption of osteoclasts via integrin-mediated signaling.

Authors:  Shinya Hayashi; Zhepeng Wang; Jennifer Bryan; Chikashi Kobayashi; Roberta Faccio; Linda J Sandell
Journal:  Bone       Date:  2011-06-25       Impact factor: 4.398

7.  3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions.

Authors:  Noam Levaot; Paul D Simoncic; Ioannis D Dimitriou; Andrew Scotter; Jose La Rose; Adeline H M Ng; Thomas L Willett; Chiachien J Wang; Salima Janmohamed; Marc Grynpas; Ernst Reichenberger; Robert Rottapel
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

8.  A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.

Authors:  V W Engleman; G A Nickols; F P Ross; M A Horton; D W Griggs; S L Settle; P G Ruminski; S L Teitelbaum
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

Review 9.  Current and potential future drug treatments for osteoporosis.

Authors:  S Patel
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

Review 10.  Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Authors:  Jochen G Schneider; Sarah R Amend; Katherine N Weilbaecher
Journal:  Bone       Date:  2010-09-17       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.